Hepatitis C-related hepatocellular carcinoma and the treatment with direct-acting antiviral agents
10.3760/cma.j.issn.1007-3418.2017.12.013
- VernacularTitle: 丙型肝炎相关性肝细胞癌与直接抗病毒药物治疗
- Author:
Xu LIU
1
;
Yanhang GAO
;
Junqi NIU
Author Information
1. Department of Hepatology, First Hospital of Jilin University, Changchun 130021, China
- Publication Type:Review
- Keywords:
Hepatitis C, chronic;
Carcinoma, hepatocellular;
Therapy;
Direct antiviral drugs
- From:
Chinese Journal of Hepatology
2017;25(12):944-947
- CountryChina
- Language:Chinese
-
Abstract:
With the wide use of direct-acting antiviral agents (DAAs), more and more patients with chronic hepatitis C achieve sustained virological response; however, no consensus has been reached on the application of DAAs in the treatment of hepatitis C virus-related hepatocellular carcinoma (HCC). This article summarizes and evaluates related issues in this field, including whether antiviral therapy with DAAs in patients with hepatitis C can increase the incidence or recurrence rate of HCC, as well as whether DAAs can be used for hepatitis C in HCC patients after antitumor treatment and the efficacy of DAAs in such patients.
